JPRN-jRCT2080221076未知2 期
A randomized, double-blind study of a combination of amlodipine and irbesartan in patients with essential hypertension who insufficiently responded to amlodipine once daily
适应症
试验速览
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 79age old（—）
- 性别
- All
入选标准
- •Patients with essential hypertension who meet one of the following criteria
- •a) Patients who are taking antihypertensive drugs
- •b) Patients who are not taking any antihypertensive drugs and whose seated systolic blood pressure (SBP) is >=160 mmHg or whose diastolic blood pressure (DBP) is >=100 mmHg
排除标准
- •Patients with renal, hepatic or heart desease
研究者
相似试验
未知
2 期
A randomized, double-blind study of a combination of amlodipine and irbesartan in patients with essential hypertension who insufficiently responded to irbesartan once dailyHypertensionJPRN-jRCT2080220753Dainippon Sumitomo Pharma Co., Ltd.
已完成
不适用
A randomised double blind study looking at combination granisetron and cyclizine anti-emetic therapy versus single use granisetron or cyclizine in day case gynaecological patientsSurgery: GynaecologicalSurgeryGynaecologicalISRCTN75581229Record provided by the NHS Trusts Clinical Trials Register - Department of Health (UK)960
进行中（未招募）
不适用
Efficacy and safety of Sarilumab and Adalimumab monotherapy in patients with Rheumatoid ArthritisRheumatoid ArthritisEUCTR2014-002541-22-GBsanofi-aventis recherche & développement340
进行中（未招募）
1 期
Efficacy and safety of Sarilumab and Adalimumab monotherapy in patients with Rheumatoid ArthritisMedDRA version: 17.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2014-002541-22-ESsanofi-aventis recherche & développement340
进行中（未招募）
1 期
Efficacy and safety of Sarilumab and Adalimumab monotherapy in patients with Rheumatoid ArthritisMedDRA version: 20.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2014-002541-22-DEsanofi-aventis recherche & développement540